SpliSense

About SpliSense

SpliSense is focused on developing transformative RNA-based treatments using Antisense Oligonucleotides (ASOs) to target the root cause of pulmonary diseases, restoring and modifying protein functionality to address untreatable conditions.

Products & Services

SPL84:A program under development for pulmonary disease treatment.

SPL5AC:A therapeutic candidate in the pipeline for pulmonary conditions.

SPL23:A program focused on addressing pulmonary health issues.

Additional Opportunities:Other potential therapeutic solutions in the pipeline.

Specialties

RNA-based therapies Antisense Oligonucleotides (ASOs) Pulmonary disease treatment Cystic Fibrosis Muco-Obstructive Pulmonary Diseases Idiopathic Pulmonary Fibrosis (IPF)

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Grant or Investment (unspecified round) T: - FT: Grant or Investment (unspecified round)	A: 8500000 MR: - FA: up to $8.5 million FAN: 8500000	D: 2024-04-03 FD: 2024-04-03	1 investors

Grant or Investment (unspecified round) Latest

2024-04-03

$8.5M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

N

Nissim Darvish

Chairman, Venture Partner at Orbimed & Managing General Partner at MeOhr Ventures

B

Batsheva Kerem

CSO & Scientific Founder

S

Stanley Fiel

Regional Chairman of Medicine at Atlantic Health

I

Ido Zairi

General Partner at Israel Biotech Fund

R

Roy Amariglio

Principal and Partner at Orbimed

L

Lior Buchman

CEO at Integra Holdings

View 9 more team members with Pro

Unlock Full Team Directory

Recent News

SpliSense Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised